Tox "exhausts" immune cells
Molecular switch for reduced immune cell function discovered
Tumors and certain viral infections pose a challenge to the human body which the immune system typically fails to hand. In these diseases it switches to hypofunctional state that prevent adequate protection. A research team from the Technical University of Munich (TUM) has achieved a major success: They were able to identify the crucial molecular switch that triggers such dysfunctional immune responses. This could make it possible in the future to switch off or to prevent this state.
Prof. Dietmar Zehn (right) with the first author of the new study about chronicle immune responses, Francesca Alfei, and his staff member Markus Flosbach.
D. Zehn / TUM
Normally, the immune system goes into a state of maximum alert following a viral infection. It triggers the activation of a variety of immune cells such as T and B cells. These procreate in large numbers, and aggressively combat the infected cells. However, if the immune system does not manage to defeat the virus, then immune cells appear with highly inhibited functions. This "exhaustion" of immune cells is triggered by the ongoing immune cell activation due to the virus. Yet, this attenuation of immune responses constitutes also a positive move for the body, as a persisting strong immune response would be a significant burden and a major cause of damage to cells and tissue. The deactivation of immune responses may also permit massive growth of tumors.
The search for a mechanism
The declared objective of tumor and infection research is to control or prevent the switching from a normal to a dysfunctional immune response. Dietmar Zehn, Professor for Animal Physiology and Immunology at the TUM School of Life Sciences Weihenstephan, has for years been interested in this kind of chronic immune response and the underlying molecular deactivation mechanisms.
"They represent the body's compromise between the damage that would be caused by an ongoing strong immune response and the actual illness itself. We're fascinated by these mechanisms for several reasons: Beside chronical infections, they also occur with tumors, have been mechanistically poorly understood in the past, and in 2018 the Nobel Prize for Medicine went to exactly this topic," says Zehn, describing the significance of the field. "In particular the demonstration by colleagues at the university hospital in Freiburg that Tox correlates with T cell dysfunction also in patients with chronic hepatitis C infections underlines the medical relevance of the observations we made."
Useful in a variety of different therapies
"It is enormously important that we have finally decoded these molecular processes: This is the absolute prerequisite for targeted modification of the processes. Controlling Tox could make it possible to reactivate weak immune responses, which would be interesting for example in fighting tumors, or to slow excessive immune responses like those found in autoimmune diseases," says Dietmar Zehn.
Protein Tox switches on "exhaustion mode"
Until now it was vaguely understood how the body switches on and regulates these immune responses. Zehn and his team found the deciding factor at the same time as two groups in the USA. The study was published in the scientific journal Nature.
The protein Tox is the decisive molecular switch. Using mouse and cell culture models together with patient samples, the scientists found out that the protein has an effect inside the cell nucleus, where it activates a genetic program that alters immune cell function. As a result, inhibitory surface receptors appear on the surface of the immune cells. The cells are thus open to inhibitory signals, ensuring that the cells "tire", functioning less effectively or even dying off.
Original publication
Francesca Alfei, Kristiyan Kanev, Maike Hofmann, Ming Wu, Hazem E. Ghoneim, Patrick Roelli, Daniel T. Utzschneider, Madlaina von Hösslin, Jolie G. Cullen, Yiping Fan, Vasyl Eisenberg, Dirk Wohlleber, Katja Steiger, Doron Merkler, Mauro Delorenzi, Percy A. Knolle, Cyrille J. Cohen, Robert Thimme, Benjamin Youngblood, and Dietmar Zehn; "Tox reinforces the phenotype and longevity of exhausted T-cells in chronic viral infection"; Nature; June 17, 2019
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
